F. Bridey

发表

Prevalence of antiphospholipid‐related antibodies in unselected patients with history of venous thrombosis

J. Amiral, M. Wolf, C. Boyer-Neumann, 1998, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Generation of antibodies to heparin‐PF4 complexes without thrombocytopenia in patients treated with unfractionated or low‐molecular‐weight heparin

J. Amiral, M. Wolf, D. Meyer, 1996, American journal of hematology.

Treatment of severe von Willebrand disease with a high‐purity von Willebrand factor concentrate (Wilfactin®): a prospective study of 50 patients

P. Mannucci, C. Rothschild, A. Borel‐Derlon, 2007, Journal of thrombosis and haemostasis : JTH.

Recombinant hirudin (HBW 023): Biological data of ten patients with severe venous thrombo‐embolism

G. Simonneau, A. Camez, F. Parent, 1995, American journal of hematology.

PLASMA D-DIMER AND PULMONARY EMBOLISM

G. Simonneau, W. Speiser, R. Dudczak, 1989, The Lancet.

Randomized Trial of Subcutaneous Low‐Molecular‐Weight Heparin CY 216 (Fraxiparine) Compared With Intravenous Unfractionated Heparin in the Curative Treatment of Submassive Pulmonary Embolism: A Dose‐Ranging Study

O. Hélénon, G. Simonneau, G. Meyer, 1992, Circulation.

Platelet Factor 4 Complexed to Heparin Is the Target for Antibodies Generated in Heparin-Induced Thrombocytopenia

J. Amiral, É. Fressinaud, M. Wolf, 1992, Thrombosis and Haemostasis.

Effect of advanced glycation end product-modified albumin on tissue factor expression by monocytes. Role of oxidant stress and protein tyrosine kinase activation.

V. Ollivier, J. Hakim, D. de Prost, 1997, Arteriosclerosis, thrombosis, and vascular biology.

Management of von Willebrand disease with a factor VIII‐poor von Willebrand factor concentrate: Results from a prospective observational post‐marketing study

S. Susen, A. Harroche, A. Borel‐Derlon, 2020, Journal of thrombosis and haemostasis : JTH.

Development of a method to separate lipoprotein-bound and lipoprotein-depleted tissue factor pathway inhibitor. Measurement of free tissue factor pathway inhibitor activity.

C. Lacombe, D. Moatti, D. de Prost, 1998, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

A Patient with Glanzmann Thrombasthenia and Epistaxis Successfully Treated with Recombinant Factor Vila

P. Steg, H. Benamer, P. Steg, 1996, Thrombosis and Haemostasis.

Antibodies to Macromolecular Platelet Factor 4-Heparin Complexes in Heparin-induced Thrombocytopenia: a Study of 44 Cases

J. Amiral, É. Fressinaud, M. Wolf, 1995, Thrombosis and Haemostasis.

Interleukin‐10 and pentoxifylline inhibit C‐reactive protein‐induced tissue factor gene expression in peripheral human blood monocytes

C. Ternisien, V. Ollivier, J. Hakim, 1994, FEBS letters.

Treatment of Severe Venous Thrombo-Embolism with Intravenous Hirudin (HBW 023): An Open Pilot Study

G. Simonneau, G. Grimon, F. Parent, 1993, Thrombosis and Haemostasis.

Interleukin‐10 inhibits endotoxin‐induced tissue factor mRNA production by human monocytes

C. Ternisien, V. Ollivier, D. de Prost, 1993, FEBS letters.

Fatal Cerebral Venous Sinus Thrombosis Associated with the Factor V Leiden Mutation and the Use of Oral Contraceptives

J. Laissy, V. Morin, D. de Prost, 1995, Thrombosis and Haemostasis.

Treatment of inherited protein C deficiency by replacement therapy with the French purified plasma‐derived protein C concentrate (PROTEXEL®)

Y. Gruel, B. Tardy, H. Chambost, 2007, Vox sanguinis.

Activation of Coagulation and Fibrinolysis in Heatstroke

S. Al-Sedairy, C. Lacombe, C. Lacombe, 1996, Thrombosis and Haemostasis.

High familial anticardiolipin antibody titer and major histocompatibility complex.

J. Piette, D. de Prost, C. Labarre, 1996, Thrombosis and haemostasis.

Impaired factor XIII activation in patients with congenital afibrinogenemia

C. Négrier, A. Casini, P. de Moerloose, 2018, Haematologica.

Treatment of homozygous protein C deficiency and neonatal purpura fulminans with a purified protein C concentrate.

J. Magny, M. Dehan, H. Schwarz, 1991, The New England journal of medicine.

Continuous Infusion of Factor VIII and von Willebrand Factor in Surgery: Trials with pdFVIII LFB or pdVWF LFB in Patients with Bleeding Disorders

B. Guillet, C. Négrier, J. Windyga, 2022, Thrombosis and haemostasis.

A Cross-over Pharmacokinetic Study of a Double Viral Inactivated Factor IX Concentrate (15 nm Filtration and SD) Compared to a SD Factor IX Concentrate

J. Goudemand, C. Négrier, H. Chambost, 1998, Thrombosis and Haemostasis.

Pharmacokinetic studies on Wilfactin®, a von Willebrand factor concentrate with a low factor VIII content treated with three virus‐inactivation/removal methods

P. Mannucci, A. Borel‐Derlon, J. Goudemand, 2005, Journal of thrombosis and haemostasis : JTH.

Pharmacology, Efficacy and Safety of a Triple-Secured Fibrinogen Concentrate in Children Less than or Equal to 12 Years with Afibrinogenaemia

Sonia Pujol, A. Harroche, C. Djambas Khayat, 2020, Thrombosis and Haemostasis.

Clinical pharmacology, efficacy and safety study of a triple‐secured fibrinogen concentrate in adults and adolescent patients with congenital fibrinogen deficiency

T. Lambert, V. Gay, C. Négrier, 2019, Journal of thrombosis and haemostasis : JTH.

Successful hip arthroplasty in an adult male with severe factor XI deficiency using Hemoleven®, a factor XI concentrate

C. Mackenzie, C. Santoro, F. Bridey, 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

Accuracy of measurements of HbF with OSM3 in neonates and infants.

J. Praud, A. Denjean, M. Dehan, 1992, The European respiratory journal.

Population pharmacokinetics of a triple‐secured fibrinogen concentrate administered to afibrinogenaemic patients: Observed age‐ and body weight‐related differences and consequences for dose adjustment in children

A. Bellon, E. Fuseau, C. Henriet, 2020, British journal of clinical pharmacology.

Accuracy of two wavelength pulse oximetry in neonates and infants

J. Praud, M. Dehan, C. Gaultier, 1989, Pediatric pulmonology.

Biological determinants of bleeding in patients with heterozygous factor XI deficiency

J. Abgrall, G. Le Gal, P. Gueguen, 2012, British journal of haematology.

Factor XI replacement for inherited factor XI deficiency in routine clinical practice: results of the HEMOLEVEN prospective 3-year postmarketing study

P. Chamouni, E. de Raucourt, J. Goudemand, 2015, Haemophilia : the official journal of the World Federation of Hemophilia.

Priapism revealing ARG 506 to GLN factor V mutation.

C. Lacombe, V. Delmas, D. de Prost, 1996, Journal of Urology.

Prenatal diagnosis in type IIA von Willebrand disease.

C. Rothschild, D. Meyer, F. Daffos, 1990, Nouvelle revue francaise d'hematologie.